Status:
TERMINATED
Distress Tolerance for Benzodiazepine Discontinuation
Lead Sponsor:
University of Pittsburgh
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Substance Use Disorders
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The proposed study is a clinical trial, designed to pilot test a Distress Tolerance-Benzodiazepine Discontinuation (DT-BD) intervention for patients on opioid agonist therapy (OAT) who currently use b...
Detailed Description
This study pilot tests a 13-week distress tolerance-based psychosocial intervention paired with a benzodiazepine taper comparing it to a relaxation therapy control condition with the aim of assisting ...
Eligibility Criteria
Inclusion
- Age 18 or older
- Receiving OAT (methadone or buprenorphine) for at least 2 weeks
- Regular BZD use defined by BZD use 3 or more times per week in past month by self-report and positive urine screen at time of recruitment
- Provides permission to contact current BZD prescriber if being prescribed BZDs
- Speaks English
- Wants to discontinue BZD use
- Capacity to provide informed consent
Exclusion
- Pregnant, confirmed by urine pregnancy test
- Cognitive impairment, as indicated by Montreal Cognitive Assessment (MoCA): must score at least 26 on the MoCA with a one-point adjustment for individuals with formal education of 12 years or fewer
- Any past month illicit opioid determined by self-report or urine drug test; illicit defined as non-medical use
- Receiving ongoing psychosocial treatment for BZD use disorder
- Uncontrolled seizure disorder (i.e. seizure in prior 90 days), or past BZD withdrawal seizure
- Current suicidality or homicidality
- Current psychotic symptoms
Key Trial Info
Start Date :
June 17 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 9 2022
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT05250570
Start Date
June 17 2022
End Date
December 9 2022
Last Update
January 30 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Psychiatric and Chemical Dependency Services (CPCDS)
Pittsburgh, Pennsylvania, United States, 15213
2
Internal Medicine Recovery Engagement Program (REP)
Pittsburgh, Pennsylvania, United States, 15219
3
Narcotic Addiction Treatment Program (NATP)
Wilkinsburg, Pennsylvania, United States, 15221